Drug Trial Radar · NCT07581834
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jan 21, 2026
Primary completion
Dec 31, 2031
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- Fujian Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 2000 HR +/HER2- early breast cancer patients who met the study criteria and were randomized in a 1:1 ratio to Column 1 and Column 2 stratified by nodal status (positive/negative), prior (neo) adjuvant chemotherapy (yes/no), and clinical/pathological stage (Stage II/III). Cohort 1 received dalcili 125 mg in combination with endocrine therapy for 2 years with dalcili; Cohort 2 received dalcili 100 mg in combination with endocrine therapy for 3 years with dalcili; treatment had to be discontinued until disease progression, intolerable adverse events, withdrawal of consent, or investigator judgment.
Conditions
- Breast Diseases
- Breast Neoplasms
- Dalpiciclib
- Endocrine Breast Diseases
- CDK4/6 Inhibitor
- HR+/HER2- Breast Cancer
Interventions
Dalpiciclib 125mgDrug
Dalpiciclib: 125 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 2 years.
Dalpiciclib 100mgDrug
Dalpiciclib: 100 mg, once daily, taken at approximately the same time every day, fasting 1 hour before and after taking the drug, for 21 consecutive days, followed by 7 days off, 28 days as a treatment cycle. It was administered for 3 years.
Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenDrug
Endocrine therapy: endocrine therapy drugs selected by the investigator, including aromatase inhibitors (AIs), fulvestrant, tamoxifen, toremifene, etc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year invasive disease-free survivalTime frame: Observed from enrollment through 3 years.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hosptial
Fuzhou, Fujian, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.